ONCOGENE, 0950-9232

Journal

  1. 2020
  2. Timaner, M., Kotsofruk, R., Raviv, Z., Magidey, K., Shechter, D., Kan, T., ... Shaked, Y. (2020). Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. ONCOGENE, 39(1), 187-203. https://doi.org/10.1038/s41388-019-0971-7
  3. 2019
  4. 2018
  5. Berns, K., Caumanns, J. J., Hijmans, E. M., Gennissen, A. M. C., Severson, T. M., Evers, B., ... Bernards, R. (2018). ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. ONCOGENE, 37(33), 4611-4625. https://doi.org/10.1038/s41388-018-0300-6
  6. Weijts, B. G. M. W., Westendorp, B., Hien, B. T., Martinez-Lopez, L. M., Zijp, M., Thurlings, I., ... de Bruin, A. (2018). Atypical E2Fs inhibit tumor angiogenesis. ONCOGENE, 37(2), 271-276. https://doi.org/10.1038/onc.2017.336
  7. 2017
  8. Thurlings, I., Lopez-Martinez, M. J., Westendorp, B., Zijp, M., Kuiper, R., Tooten, PCJ., ... de Bruin, A. (2017). Synergistic functions of E2F7 and E2F8 are critical to suppress stress-induced skin cancer. ONCOGENE, 36(6), 829-839. https://doi.org/10.1038/onc.2016.251
  9. De Cian, M-C., Pauper, E., Bandiera, R., Vidal, V. P. I., Sacco, S., Gregoire, E. P., ... Chaboissier, M-C. (2017). Amplification of R-spondin1 signaling induces granulosa cell fate defects and cancers in mouse adult ovary. ONCOGENE, 36, 208-218. https://doi.org/10.1038/onc.2016.191
  10. 2016
  11. 2015
  12. O'Leary, L., van der Sloot, A. M., Reis, C. R., Deegan, S., Ryan, A. E., Dhami, S. P. S., ... Szegezdi, E. (2015). Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. ONCOGENE, 35, 1261–1270. https://doi.org/10.1038/onc.2015.180
  13. 2013
  14. 2012
  15. Zeller, C., Dai, W., Steele, N. L., Siddiq, A., Walley, A. J., Wilhelm-Benartzi, C. S. M., ... Brown, R. (2012). Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. ONCOGENE, 31(42), 4567-4576. https://doi.org/10.1038/onc.2011.611
  16. 2011
  17. Rovillain, E., Mansfield, L., Caetano, C., Alvarez-Fernandez, M., Caballero, O. L., Medema, R. H., ... Jat, P. S. (2011). Activation of nuclear factor-kappa B signalling promotes cellular senescence. ONCOGENE, 30(20), 2356-2366. https://doi.org/10.1038/onc.2010.611
  18. 2010
  19. 2009
  20. Tanuma, N., Nomura, M., Ikeda, M., Kasugai, I., Tsubaki, Y., Takagaki, K., ... Shima, H. (2009). Protein phosphatase Dusp26 associates with KIF3 motor and promotes N-cadherin-mediated cell-cell adhesion. ONCOGENE, 28(5), 752-761. https://doi.org/10.1038/onc.2008.431
  21. van Gorp, A. G. M., van der Vos, K. E., Brenkman, A. B., Bremer, A., van den Broek, N., Zwartkruis, F., ... Coffer, P. J. (2009). AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. ONCOGENE, 28(1), 95-106. https://doi.org/10.1038/onc.2008.367
  22. 2008
  23. van der Vos, K. E., & Coffer, P. J. (2008). FOXO-binding partners: it takes two to tango. ONCOGENE, 27(16), 2289-2299. https://doi.org/10.1038/onc.2008.22
  24. Foijer, F., Simonis, M., van Vliet, M., Wessels, L., Kerkhoven, R., Sorger, P. K., & Te Riele, H. (2008). Oncogenic pathways impinging on the G2-restriction point. ONCOGENE, 27(8), 1142-1154. https://doi.org/10.1038/sj.onc.1210724
  25. 2007
  26. Küsters, B., Kats, G., Roodink, I., Verrijp, K., Wesseling, P., Ruiter, D. J., ... Leenders, W. P. J. (2007). Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis. ONCOGENE, 26(39), 5808-5815. https://doi.org/10.1038/sj.onc.1210360
  27. Davalos, V., Dopeso, H., Velho, S., Ferreira, A. M., Cirnes, L., Diaz-Chico, N., ... Arango, D. (2007). High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. ONCOGENE, 26(2), 308-311. https://doi.org/10.1038/sj.onc.1209780
  28. 2006
  29. Bos, C. L., Kodach, L. L., van den Brink, G. R., Diks, S. H., van Santen, M. M., Richel, D. J., ... Hardwick, J. C. H. (2006). Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. ONCOGENE, 25(49), 6447-6456. https://doi.org/10.1038/sj.onc.1209658
  30. 2005
  31. Oliveira, C., Velho, R., Domingo, E., Preto, A., Hofstra, RMW., Hamelin, R., ... Schwartz, S. (2005). Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. ONCOGENE, 24(51), 7630-7634. https://doi.org/10.1038/sj.onc.1208906
  32. Chan, E. H. Y., Nousiainen, M., Chalamalasetty, R. B., Schäfer, A., Nigg, E. A., & Silljé, H. H. W. (2005). The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. ONCOGENE, 24(12), 2076-86. https://doi.org/10.1038/sj.onc.1208445
  33. 2004
  34. 2003
  35. Krause, D. R., Jonnalagadda, J. C., Gatei, M. H., Sillje, H. H. W., Zhou, B-B., Nigg, E. A., & Khanna, K. (2003). Suppression of Tousled-like kinase activity after DNA damage or replication block requires ATM, NBS1 and Chk1. ONCOGENE, 22(38), 5927-37. https://doi.org/10.1038/sj.onc.1206691
  36. Silva, F. P. G., Morolli, B., Storlazzi, C. T., Anelli, L., Wessels, H., Bezrookove, V., ... Giphart-Gassler, M. (2003). Identification of RUNX1/AML1 as a classical tumor suppressor gene. ONCOGENE, 22(4), 538 - 547. https://doi.org/10.1038/sj.onc.1206141
  37. 2001
  38. Schuringa, JJ., Wojtachnio, K., Hagens, W., Vellenga, E., Buys, CHCM., Hofstra, R., & Kruijer, W. (2001). MEN2A-RET-induced cellular transformation by activation of STAT3. ONCOGENE, 20(38), 5350-5358.
  39. 1998
  40. Mostert, MC., Verkerk, AJMH., van de Pol, M., Heighway, J., Marynen, P., Rosenberg, C., ... Looijenga, LHJ. (1998). Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults. ONCOGENE, 16(20), 2617-2627.
  41. 1997
  42. Coffer, PJ., vanPuijenbroek, A., Burgering, BMT., KlopdeJonge, M., Koenderman, L., Bos, JL., & Kruijer, W. (1997). Insulin activates Stat3 independently of p21ras-ERK and PI-3K signal transduction. ONCOGENE, 15(21), 2529-2539.
  43. Brown, R., Hirst, GL., Gallagher, WM., McIlwrath, AJ., Margison, GP., vanderZee, AGJ., & Anthoney, DA. (1997). hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. ONCOGENE, 15(1), 45-52.
  44. 1996
  45. Todd, MC., Xiang, RH., Garcia, DK., Kerbacher, KE., Moore, SL., Hensel, CH., ... Naylor, SL. (1996). An 80 Kb P1 clone from chromosome 3p21.3 suppresses tumor growth in vivo. ONCOGENE, 13(11), 2387-2396.
  46. 1995
  47. PASINI, B., HOFSTRA, RMW., YIN, L., BOCCIARDI, R., SANTAMARIA, G., GROOTSCHOLTEN, PM., ... ROMEO, G. (1995). THE PHYSICAL MAP OF THE HUMAN RET PROTOONCOGENE. ONCOGENE, 11(9), 1737-1743.
  48. COFFER, PJ., BURGERING, BMT., PEPPELENBOSCH, MP., BOS, JL., & KRUIJER, W. (1995). UV ACTIVATION OF RECEPTOR TYROSINE KINASE-ACTIVITY. ONCOGENE, 11(3), 561-569.
  49. COFFER, P., LUTTICKEN, C., VANPUIJENBROEK, A., KLOPDEJONGE, M., HORN, F., & KRUIJER, W. (1995). TRANSCRIPTIONAL REGULATION OF THE JUNB PROMOTER - ANALYSIS OF STAT-MEDIATED SIGNAL-TRANSDUCTION. ONCOGENE, 10(5), 985-994.
  50. 1994
  51. CECCHERINI, N. V., HOFSTRA, RMW., LUO, Y., STULP, RP., BARONE, N. V., STELWAGEN, T., ... ROMEO, G. (1994). DNA POLYMORPHISMS AND CONDITIONS FOR SSCP ANALYSIS OF THE 20 EXONS OF THE RET PROTOONCOGENE. ONCOGENE, 9(10), 3025-3029.
  52. COFFER, P., DEJONGE, M., METTOUCHI, A., BINETRUY, B., GHYSDAEL, J., & KRUIJER, W. (1994). JUNB PROMOTER REGULATION - RAS MEDIATED TRANSACTIVATION BY C-ETS-1 AND C-ETS-2. ONCOGENE, 9(3), 911-921.
  53. 1993
  54. Leeuw, B. D., Suijkerbuijk, R. F., Balemans, M., Sinke, R. J., de Jong, B., Molenaar, W. M., ... Hofker, M. (1993). Sublocalization of the synovial sarcoma-associated t(X;18) chromosomal breakpoint in Xp11.2 using cosmid cloning and fluorescence in situ hybridization. ONCOGENE, 8(6), 1457-1463.

ID: 1517535